News

Ibrance is an oral, first-in-class inhibitor of cyclin-dependent kinases (CDKs) 4 and 6, which are key regulators of the cell cycle that trigger cellular progression. With the validation

VL-2397 (ASP2397) is part of a potential new class of antifungal compounds for the treatment of systemic fungal infections, which are major causes of morbidity and mortality in

The first patient dosed is suffering from advanced adrenal cell carcinoma (ACC) and received a siRNA that blocks cell division. The company is focused on developing its proprietary

PD-1 inhibitor, also called a checkpoint inhibitor, works by exposing cancer cells to attack by the immune system by preventing the cancer cells from blocking an effective immune

Resunab is a new synthetic oral endocannabinoid-mimic drug that preferentially binds to a receptor called CB2 on immune cells and fibroblasts. According to several pre-clinical and ex-vivo models,

Currently, solithromycin is in Phase III development for the treatment of CABP and submission of a new drug application (NDA) is planned for 2016. The company is carrying

Earlier, drisapersen has also secured orphan and fast track status, breakthrough therapy designation, as well as priority review status from the FDA. According to FDA, a rare pediatric

The deal will see Valeant pay all cash, one $500m installment upfront and the remaining next year to Sprout, according to the Wall Street Journal. Under the deal,

Developed for the prescription market and formulated with the patented Microcyn Technology, the product is being made available via the company’s dermatology division IntraDerm Pharmaceuticals. Alevicyn SG Antipruritic